Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study
Authors:
- Hiroshi UrakawaHUHiroshi Urakawa
- Tsukasa YonemotoTYTsukasa Yonemoto
- Seiichi MatsumotoSMSeiichi Matsumoto
- Tatsuya TakagiTTTatsuya Takagi
- Kunihiro AsanumaKAKunihiro Asanuma
- Munenori WatanukiMWMunenori Watanuki
- Akira TakemotoATAkira Takemoto
- Norifumi NakaNNNorifumi Naka
- Yoshihiro MatsumotoYMYoshihiro Matsumoto
- Akira KawaiAKAkira Kawai
- Toshiyuki KunisadaTKToshiyuki Kunisada
- Tadahiko KuboTKTadahiko Kubo
Open Access
- 8 August 2018
- journal article
- research article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 16 (1) , 1-8
Abstract
Giant cell tumor of bone (GCTB) is an intermediate tumor known to be locally aggressive, but rarely metastasizing. To plan a prospective study of GCTB, we performed a questionnaire survey for institutions participating in the Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) in 2015. We reviewed 158 consecutive patients with primary GCTB treated with curettage without perioperative denosumab from 2008 to 2010 in Japan. We investigated local and distant recurrence rates after definitive curettage. We also investigated the recurrence rate after treatment with preoperative and/or postoperative denosumab with curettage in recent years. There were 40 patients treated with perioperative denosumab, and the factors affecting recurrence in them were investigated. Answers were available from 24 of 30 institutions (80.0%) participating in JCOG BSTTSG. Thirty (19.0%) and 4 (2.5%) of 158 patients developed local and distant recurrence after curettage without perioperative denosumab from 2008 to 2010, respectively. Campanacci grade and embolization before surgery were significantly associated with increasing incidence of local recurrence after curettage (p = 0.034 and p = 0.022, respectively). In patients treated with perioperative desnosumab, 120 mg denosumab was administered subcutaneously for a median 6 (2–41) and 6 (1–14) times in preoperative and postoperative settings, respectively. The recurrence rates were 6 of 21 (28.6%), 2 of 9 (22.2%), and 0 of 10 (0.0%) in the preoperative, postoperative, and both pre- and postoperative denosumab treatment groups, respectively. With all of the preoperative treatments, administration exceeding five times was significantly associated with a decreased incidence of local recurrence after curettage (p < 0.001). The recurrence rate of GCTB was still high after curettage, especially in Campanacci grade III, and improvements in the therapeutic strategy are needed in this cohort. There is a possibility that a sufficient dose of preoperative denosumab can reduce recurrence after curettage. Recently, we have started a clinical trial, JCOG1610, to investigate the efficacy of preoperative denosumab in patients who can be treated with curettage in GCTB.Keywords
This publication has 24 references indexed in Scilit:
- Reproductive toxicity of denosumab in cynomolgus monkeysReproductive Toxicology, 2013
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-HealingJournal of Bone and Joint Surgery, 2012
- Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneClinical Cancer Research, 2012
- Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical ManagementClinical Orthopaedics and Related Research, 2011
- The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology GroupJournal of Orthopaedic Science, 2011
- Treatment of Giant Cell Tumor of Long Bones: Clinical Outcome and Reconstructive Strategy for Lower and Upper LimbsOrthopedics, 2009
- Local Recurrence of Giant Cell Tumor of Bone After Intralesional Treatment with and without Adjuvant TherapyJournal of Bone and Joint Surgery, 2008
- Giant cell tumor of bone: treatment and outcome of 214 casesJournal of Cancer Research and Clinical Oncology, 2008
- Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell TumorsJournal of Bone and Mineral Research, 2000